Detalhe da pesquisa
1.
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
Rheumatology (Oxford)
; 62(6): 2113-2121, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282530
2.
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Clin Exp Rheumatol
; 41(11): 2286-2297, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37404160
3.
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Ann Rheum Dis
; 81(2): 225-231, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911706
4.
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Ann Rheum Dis
; 80(3): 312-320, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33272960
5.
Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis.
Mod Rheumatol
; 24(6): 980-4, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24884480
6.
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Rheumatol Ther
; 11(3): 617-632, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38498141
7.
To be or not to B27 positive: implications for the phenotypes of axial spondyloarthritis outcomes. Data from a large multiracial cohort from the Brazilian Registry of Spondyloarthritis.
Adv Rheumatol
; 64(1): 33, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38671475
8.
Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study.
Ann Rheum Dis
; 70(11): 2003-7, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21914628
9.
Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy.
Int J Rheum Dis
; 24(12): 1530-1539, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779576
10.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Rheumatol Ther
; 8(2): 903-919, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33913086
11.
Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis.
Adv Rheumatol
; 61(1): 69, 2021 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819174
12.
Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis.
Adv Rheumatol
; 61(1): 4, 2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33468245
13.
Lupoid sclerosis.
Rheumatol Int
; 30(4): 431-4, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19826821
14.
The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019.
Adv Rheumatol
; 60(1): 19, 2020 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32171329
15.
Serum IL-6 correlates with axial mobility index (Bath Ankylosing Spondylitis Metrology Index) in Brazilian patients with ankylosing spondylitis.
Open Access Rheumatol
; 10: 21-25, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750059
16.
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
J Rheumatol
; 45(8): 1085-1092, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29657147
17.
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Arthritis Rheumatol
; 69(2): 362-375, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27598855
18.
Quality of life in spondyloarthritis: analysis of a large Brazilian cohort.
Rev Bras Reumatol Engl Ed
; 56(1): 22-7, 2016.
Artigo
em Inglês, Português
| MEDLINE | ID: mdl-27267330
19.
Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis
Adv Rheumatol
; 61: 4, 2021. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-1152735
20.
[Evaluation of performance of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) in a Brazilian cohort of 1,492 patients with spondyloarthritis: data from the Brazilian Registry of Spondyloarthritides (RBE)]. / Avaliação do desempenho do BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) numa coorte brasileira de 1.492 pacientes com espondiloartrites: dados do Registro Brasileiro de Espondiloartrites (RBE).
Rev Bras Reumatol
; 55(1): 48-54, 2015.
Artigo
em Português
| MEDLINE | ID: mdl-25542672